Sarcopenia and myosteatosis are associated with low survival in patients receiving lenvatinib for unresectable hepatocellular carcinoma
LSMM and myosteatosis are independent prognostic factors for PFS and OS in advanced patients with HCC who received LEN and may exert synergistic effects on these survival outcomes.
Authors
- Yao‐Yu Hsieh (ORCID: https://orcid.org/0000-0003-4368-4281)
- Pei-Jui Luo
- Wei‐Yu Kao (ORCID: https://orcid.org/0000-0002-5506-4293)
- Kai-I Chuang (ORCID: https://orcid.org/0000-0002-8020-7970)
- Ming‐Shun Wu (ORCID: https://orcid.org/0000-0002-5755-9062)
- Hong‐Zen Yeh (ORCID: https://orcid.org/0000-0002-2726-604X)
- Cheng-Fu Ni
- Chih‐Horng Wu (ORCID: https://orcid.org/0000-0002-7498-4183)
Institutions
- Taipei Medical University Hospital (TW)
- National Taiwan University Hospital (TW)
- Taipei Medical University-Shuang Ho Hospital (TW)
- Taipei Medical University (TW)
Publication Details
- Journal
- Journal of the Formosan Medical Association
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1016/j.jfma.2025.01.001
- Citations
- 7
- Primary Topic
- Nutrition and Health in Aging
- Type
- article
- Field-Weighted Citation Impact
- 8.15
Funders
- Ministry of Health and Welfare
- National Taiwan University Hospital